Insider Selling: Annexon, Inc. (NASDAQ:ANNX) EVP Sells 5,408 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 5,408 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total value of $40,073.28. Following the sale, the executive vice president now owns 71,365 shares of the company’s stock, valued at approximately $528,814.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ted Yednock also recently made the following trade(s):

• On Thursday, September 19th, Ted Yednock sold 4,500 shares of Annexon stock. The shares were sold at an average price of $7.10, for a total value of $31,950.00.
• On Thursday, September 5th, Ted Yednock sold 5,500 shares of Annexon stock. The stock was sold at an average price of $5.64, for a total transaction of $31,020.00.
• On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The stock was sold at an average price of $5.95, for a total transaction of $32,725.00.

Annexon Stock Up 0.1 %

NASDAQ ANNX opened at $7.63 on Friday. Annexon, Inc. has a twelve month low of $1.67 and a twelve month high of $8.40. The stock has a market cap of $705.11 million, a P/E ratio of -5.19 and a beta of 1.28. The company’s 50-day simple moving average is $6.33 and its 200 day simple moving average is $5.66.

Annexon (NASDAQ:ANNX) last issued its earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.23). Research analysts anticipate that Annexon, Inc. will post -0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ANNX shares. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Annexon in a report on Tuesday, August 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Monday, September 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $15.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its position in shares of Annexon by 78.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after purchasing an additional 2,949 shares in the last quarter. Sandia Investment Management LP acquired a new stake in shares of Annexon during the second quarter worth approximately $49,000. Victory Capital Management Inc. bought a new position in shares of Annexon in the second quarter valued at approximately $51,000. Principal Financial Group Inc. bought a new position in shares of Annexon in the second quarter valued at approximately $56,000. Finally, Comerica Bank acquired a new position in shares of Annexon in the 1st quarter worth approximately $72,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.